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Abstract Alzheimer’s disease (AD) is a multifactorial dis-
ease of wide clinical heterogenity. Overproduction of amyloid
precursor protein (APP) and accumulation of β-amyloid
(Aβ) and tau proteins are important hallmarks of AD. The
identification of early pathomechanisms of AD is critically
important for discovery of early diagnosis markers.
Decreased brain metabolism is one of the earliest clinical
symptoms of AD that indicate mitochondrial dysfunction in
the brain. We performed the first comprehensive study inte-
grating synaptic and non-synaptic mitochondrial proteome
analysis (two-dimensional differential gel electrophoresis
(2D-DIGE) and mass spectrometry) in correlation with Aβ
progression in APP/PS1 mice (3, 6, and 9 months of age). We
identified changes of 60 mitochondrial proteins that reflect
the progressive effect of APP overproduction and Aβ accu-
mulation on mitochondrial processes. Most of the significant-
ly affected proteins play role in the mitochondrial electron
transport chain, citric acid cycle, oxidative stress, or apopto-
sis. Altered expression levels of Htra2 and Ethe1, which
showed parallel changes in different age groups, were con-
firmed also by Western blot. The common regulator
bioinformatical analysis suggests the regulatory role of tumor
necrosis factor (TNF) in Aβ-mediated mitochondrial protein
changes. Our results are in accordance with the previous
postmortem human brain proteomic studies in AD in the case
of many proteins. Our results could open a new path of re-
search aiming early mitochondrial molecular mechanisms of
Aβ accumulation as a prodromal stage of human AD.
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Abbreviations
sMito Synaptic mitochondria
nsMito Non-synaptic mitochondria
Aβ Amyloid-β
2D-DIGE Two-dimensional differential gel electrophoresis
WB Western blot
Htra2 Serine protease HTRA2
Ethe1 Persulfide dioxygenase ETHE1
APP Amyloid precursor protein
PS1 Presenilin-1
Introduction
Neurodegenerative disorders such as Alzheimer’s,
Parkinson’s, Huntington’s disease (AD, PD, HD), and pri-
on diseases show several high importance similarities, in-
cluding neuronal loss and aggregation of disease-specific
misfolded proteins in the brain. These disorders belong to
the family of “protein conformational” diseases [1].
Overlapping of the misfolded proteins is typical in neuro-
degenerative diseases: multiple toxic proteins are accumu-
lated in AD and other age-related disorders [2]. Formation
and accumulation of misfolded proteins demonstrate that
failure in ATP production, protein folding, and quality
control may play an important role in the pathological
processes [3]. Precipitation of two main proteins (β-amy-
loid/Aβ and hyperphosphorylated tau) is typical in AD
brain.
There are two main forms of AD: the early onset/familial
and the late onset/sporadic form. Familial AD is caused by
mutations of the amyloid precursor protein (APP) and the
γ-secretase complex (presenilin-1 and presenilin-2/PS1 and
2) [4]. On the basis of clinical presentation, there are several
further subtypes of AD (amnestic, pure amnestic, language,
visuoperceptive, and executive variants) [5]. All subtypes of
AD share common pathological hallmarks like the presence of
amyloid plaques and neurofibrillary tangles. Consequently,
amyloidogenic APP processing and tau hyperphosphorylation
must be key events in the progress of AD.
Formation of amyloid plaques in the brain is also a
frequent hallmark of aging without dementia [6]. It has
been more and more accepted that Aβ accumulation itself
is not necessarily the initial step of AD [7], only a conse-
quence of preceding molecular events. However, Aβ ac-
cumulation is still an important issue in AD progression,
because intracellular Aβ has toxic effects in synaptic
transmission and memory trace formation as well as de-
creases the number of synapses [8].
The early Aβ accumulation-induced molecular mech-
anisms cannot be studied in humans due to ethical prob-
lems of brain biopsy, and thus, animal models should be
used. One of the best models is the double transgenic
APP /PS1 mouse , exp r e s s i ng bo th the human
Swedish-mutant APP and a mutant PS1 [9, 10].
Cleavage of APP by β- and γ-secretase generates both
Aβ and APP intracellular domain (AICD) peptides [11];
therefore, beside Aβ accumulation, AICD peptide level
also increases in APP/PS1 mice. These animals reproduce
a common process in most variants of AD. APP/PS1 mice
also reproduce some symptoms of AD, such as the
age-dependent synaptic dysfunction and memory loss [9,
12] as well as metabolic changes due to mitochondrial
dysfunction [6, 8, 10], which are characteristic for human
AD as well.
It has been revealed that overproduced APP and Aβ
are present in the mitochondria of APP transgenic mouse
models and human AD brain [13–15]. The presence of
mitochondrial Aβ correlates well with mitochondrial dys-
function in the synapses [16] because synaptic mitochon-
dria are particularly sensitive to Aβ [17]. Aβ is present in
the synaptic mitochondria of APP/PS1 transgenic mice at
early stage, when no accumulation of extracellular Aβ
can be detected [17].
Mitochondrial failure and dysfunction are an early
sign of AD and other neurodegenerative disorders [10,
18–20]. Brain hypometabolism and progressive decrease
of brain metabolism are the earliest clinical symptoms
of AD [1]. Selection of high-risk potential AD groups
of aging humans, before manifestation of cognitive im-
pairment, represents an important aim of AD research.
Changes in the level of individual mitochondrial pro-
teins could serve as early metabolic markers for AD.
Because of limitations of human studies, a necessary
compromise could be the use of the double transgenic
APP/PS1 mouse as a proper model for studying early
molecular mechanisms of AD.
Mitochondrial proteome changes in AD models
[21–24] and the postmortem brain human proteomics data
of AD [25–29] confirm the possibility of early mitochon-
drial protein markers for AD. However, the already pub-
lished mitochondrial proteomics data are incoherent be-
cause of using different animal models and different time
points of investigation in AD development. Therefore, a
coherent , comprehensive study of synapt ic and
non-synaptic mitochondrial proteome of animal model of
AD is needed to reveal early molecular mechanisms of
AD. Our aim was to conduct a systematic study of prote-
ome changes in synaptic (sMito) and non-synaptic mito-
chondria (nsMito) of APP/PS1 mice at different ages.
The present study focuses on two major questions: (i)
Are there Aβ-induced mitochondrial proteome changes
as early as 3 months of age in APP/PS1 mice without
behavioral changes? (ii) How do the synaptic and/or
non-synaptic mitochondrial proteomes change in the
time frame of 3 to 9 months of age?
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Methods
Animal Model
The APP/PS1 mice carry the Mo/Hu APP695swe (695-amino
acid isoform of human APP) and PS1-dE9 (mutant human
PS1) mutations. PS1-dE9 alters the specificity of γ-secretase
to favor production of Aβ42 and consequently shifts the ratio
of Aβ40/Aβ42. Experiments begun with 3-month-old animals
without amyloid deposits and behavioral changes. Aβ de-
posits appear at 6 months of age mostly in the cerebral cortex,
while the amyloid plaques are abundant in the hippocampus
and cerebral cortex at 9 months of age [30]. Performance of
APP/PS1 mice in the Morris water maze gradually declines
between 3 and 12 months of age [31]. Therefore, we selected
3-, 6-, and 9-month-old APP/PS1 and C57BL/6 (B6) control
mice for proteomics (n=36) and light microscopy experi-
ments (n= 12). Handling and experimentation on animals
were performed in conform to Council Directive 86/609/
EEC, the Hungarian Act of Animal Care, and the
Experimentation (1998, XXVIII) and local regulations for
care and use animals for research.
β-Amyloid Progression Detection in 3-, 6-,
and 9-Month-Old APP/PS1 Mice Brain
All reagents used for microscopy were obtained from
Sigma-Aldrich. Twelve mice were used for microscopic in-
vestigations (two mice per group). Brains were transcardially
perfused with saline then with 4 % formaldehyde, 0.05 %
glutaraldehyde, and 0.2 % saturated picric acid in 0.1 M phos-
phate buffer (pH=7.4; PB) for 25 min. The brains were left in
the skull overnight. Blocks containing the dorsal hippocampus
were sectioned at 50 μm with a vibratome VT 1000S (Leica)
and stored in 0.1 M PB supplemented with 0.05 % sodium
azide. Sections were washed with 0.1 M Na-cacodylate and
postfixed in reduced osmium (0.5 % osmium tetroxide,
0 .75 % potas s ium hexacyano- f e r r a t e in 0 .1 M
Na-cacodylate) for 60 min, en bloc stained with
half-saturated aqueous uranyl acetate, dehydrated, and flat
embedded on slides in Durcupan resin (Fluka). Sections were
photographed with a Zeiss Axio Imager Z1 microscope
(Zeiss) equipped with a Cc1 camera.
For electron microscopy, the coverslips were removed,
and small pieces from the somatosensory cortex and dor-
sal hippocampus were re-embedded. Ultrathin sections
(70 nm) were collected on 300-mesh copper grids and
stained with uranyl acetate for 5 min and lead citrate for
30 s. Grids were examined in JEOL JEM 1011 electron
microscope (JEOL) operating at 60 kV. Images were taken
with an Olympus Morada 11-MP camera (Olympus) and
iTEM software (Olympus).
Isolation of Synaptic and Non-synaptic Mitochondria
Metabolically active sMito and nsMito were isolated accord-
ing to our already published protocol [32]. Briefly, mice were
decapitated and the brains rapidly removed, washed in artifi-
cial cerebrospinal fluid (ACSF), and immediately cooled in
dry ice. Brain tissue (weighing 200 mg per animal) was ho-
mogenized in 700 μL of ice-cold isolation buffer (225 mM
mannitol, 75 mM sucrose, 20 mM HEPES-KOH, 1 mM
EGTA, protease and phosphatase inhibitor cocktails, pH ad-
justed to 7.2 with KOH) using pre-chilled Dounce homoge-
nizer (Kontes Glass Co.; eight-stroke large clearance +
eight-stroke small clearance). All steps were performed at
4 °C or on ice with ice-cold buffers and solutions. The resul-
tant homogenates were centrifuged at 1300g for 5 min.
Supernatants were collected, and an equal volume of 30 %
Percoll in isolation buffer was added. The resultant homoge-
nate was layered with 1-mL syringe (Tuberculin, 0.5×25-mm
needle) on a discontinuous Percoll gradient (with the bottom
layer containing 40 %, followed by a 24 %, and, finally, the
sample in 15 % Percoll solution) and centrifuged at 34,000g
for 8 min. After centrifugation, band 2 (the interface between
15 and 23 % containing synaptosome) and band 3 (the inter-
face between 23 and 40 % containing nsMito) were collected
from the density gradient, using a tight bore medical needle
(26 gauge) and a 2-mL syringe. The samples were transferred
to another centrifuge tube by manually pushing through again
in the same tight bore needle with high speed. As the synap-
tosomal fraction was getting through the needle, it became
fractured by the sheer force and the internal synaptic mito-
chondria were released. The samples were diluted with four
volumes of isolation buffer and centrifuged at 34,000g for
8 min. The resultant loose pellets containing exclusively the
sMito or nsMito were collected and washed at 8000g for
15 min. The final sMito and nsMito pellets were precipitated
overnight in ice-cold acetone. The electron microscopic and
fluorescence-activated cell sorting (FACS) validation of sMito
and nsMito samples have already been published [32].
Proteomic Analysis by 2D-DIGE
The detailed two-dimensional differential gel electrophoresis
(2D-DIGE) protocol has been described in our earlier studies
[32, 33]. We used 2D-DIGE Saturation Labeling method.
Equipment and software were supplied from GE Healthcare,
Little Chalfont, UK. Briefly, acetone-precipitated mitochon-
drial samples were resuspended in a lysis buffer containing
7 M urea, 2 M thiourea, 4 % CHAPS, 20 mM Tris, and 5 mM
magnesium-acetate. The pH was adjusted to 8.0, and the pro-
tein concentrations were determined by 2D-Quant Kit.
Samples of 5 μg were labeled by using CyDye DIGE Fluor
Saturation Labeling Kit according to the manufacturer’s in-
structions. The sMito and nsMito samples were labeled with
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Cy5, and the internal standard (pool of equal amounts of all
samples within the experiment) was labeled with Cy3. The
two differently labeled protein samples were merged, and 12
mixtures (six-six gels simultaneously) were run. Isoelectric
focusing was performed on 24-cm immobilized pH gradient
(IPG) strips (pH 3–10 NL) for 24 h in an Ettan IPGphor
instrument, to attain a total of 80 kVh. The applied voltages
were as follows: 30 V for 3-h step, 500 V for 5 h gradient,
1000 V for 6 h gradient, 8000 V for 3 h gradient, and 8000 V
for 6-h step mode. Focused proteins were reduced in equili-
brating buffer containing 6 M urea, 50 mM Tris (pH 8.8),
30 % (v/v) glycerine, 2 % (w/v) sodium dodecyl sulfate
(SDS), Bromophenol Blue (trace), and 1 % (w/v)
mercaptoethanol for 20 min. Subsequently, the IPG strips
were loaded onto 10 % polyacrylamide gels (24×20 cm),
and SDS-PAGE was performed using an Ettan DALT Six
System. Gels were scanned in a Typhoon TRIO+ scanner
selecting appropriate lasers and filters. Gel images were visu-
alized by ImageQuant TL software.
Differential protein analysis was performed using
DeCyderTM 2D software 7.0 Differential In-gel Analysis
(DIA) and Biological Variance Analysis (BVA) modules.
The internal standard sample was the same in all gels, and
fluorescent intensity changes of protein spots were normalized
to the values of the corresponding internal standard. It provid-
ed an image, against which, all other gel images were normal-
ized. Independent Student’s t test was performed to determine
the statistical significance of the protein abundance changes
for each protein spot.
Preparative 2D Gel Electrophoresis for Protein
Identification
For the identification of proteins in spots of interest, prepara-
tive 2D gel electrophoresis was performed, separately, using a
total of 800 μg of proteins per gel. Resolved protein spots
were visualized by Colloidal Coomassie Blue G-250
(Merck, Darmstadt, Germany).
Protein Identification by Mass Spectrometry
(nanoUHPLC-MS/MS)
Digested protein samples were analyzed on a Waters
nanoACQUITY UPLC sys t em coup l ed wi th a
Micromass Q-TOF premier mass spectrometer. The sam-
ples (5-μL full-loop injection) were initially transferred
with an A eluent to the pre-column at a flow rate of
10 μL/min for 1 min. Mobile phase A was 0.1 % formic
acid in water whilst mobile phase B was 0.1 % formic
acid in acetonitrile with 350 nL/min flow rate which were
applied on a Waters BEH130 C-18 75 μm×250 mm col-
umn with 1.7-μm particle size C-18 packing. The linear
gradient was as follows: 3–10 % B over 0–1 min, 10–
30 % B over 1–20 min, and 30–100 % B over 20–
21 min, and the composition was maintained 100 % B
for 1 min and then returned to 3 % during 1 min. The
column was re-equilibrated at initial conditions for
22 min. The column was maintained at 45 °C. The mass
spectrometer operated in DDA mode with lock mass cor-
rection, with a nominal mass accuracy of 3 ppm. The
instrument was operated in positive ion mode, performing
full-scan analysis over the m/z range 400–1990 at 1/1
spectra/s for mass spectrometry (MS) and 50–1990 in MS/
MS. The source temperature was set at 85 °C, and nitrogen
was used as the desolving gas (0.5 bar). Capillary voltage and
cone voltage were maintained at 3.3 kVand 26V, respectively.
Data were processed by the WATERS ProteinLynx
Global Server 2.4 software using default settings.
Database search was performed by Mascot 2.2 (Matrix
Science, London, UK) which was set up to search
Swissprot database adjusted to tryptic digestion. Data
were searched with 0.15-Da fragment and 30-ppm par-
ent ion mass tolerances. Oxidation of methionine was
specified as a variable modification.
Scaffold software (version Scaffold 3.62, Proteome
Software Inc., Portland, OR) was used to validate MS/
MS-based peptide and protein detection. Protein identifica-
tions were accepted if the probability was higher than
95.0 % and contained at least two identified peptides.
Protein probabilities were assigned by the Protein
Prophet algorithm.
Functional Clustering
Significantly altered proteins were clustered on the basis of the
UniProt (http://www.uniprot.org/) and Gene Ontology (http://
geneontology.org/) databases. The proteins were clustered in
groups according to their most relevant cellular functions, and
roles in human AD pathology were also listed.
Bioinformatical Analysis of Mitochondrial Protein
Changes
We analyzed the interactions between significantly changed
mitochondrial proteins with Ariadne Genomics Pathway
Studio® 9.0 software environment (ResNet 9.0, 2010Q4,
Ariadne Genomics, Inc, Rockville, MD, USA) [34].
Common regulator and common target analysis were
made for all mitochondrial protein changes (altogether
sMito and nsMito at 3, 6, and 9 months of age). We
selected for further analysis common regulator and tar-
get proteins, having minimum seven relationships with
significantly changed mitochondrial proteins from our
experimental results.
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Htra2 and Ethe1 Protein Validation by WB
The highest fold differences in the altered synaptic mi-
tochondrial proteins that showed significant protein-level
changes in all three age groups were Htra2 and Ethe1;
thus, we selected them for validation by Western blot.
We used the same synaptic mitochondrial samples as
utilized in the 2D-DIGE method. Proteins were separat-
ed by Tricine-SDS-polyacrylamide gel electrophoresis
on 15 % polyacrylamide gels then transferred to
HybondTM-LFP PVDF transfer membranes (GE
Healthcare). The membranes were blocked with 5 %
BSA in Tris-buffered saline and 0.1 % Tween 20
(TBS-T) and then washed in TBS-T. The blots were
incubated with the following primary antibodies: rabbit
an t i -H t r a2 po lyc lona l an t i body (15775-1 -AP,
Proteintech) at 1:1000 and rabbit anti-Ethe1 polyclonal
antibody (ab154041; Abcam) at 1:500 dilution.
Subsequently, the membranes were washed 4 × 5 min
in TBS-T followed by the incubation with ECL Plex
CyDye-conjugated anti-rabbit IgG secondary antibody
(GE Healthcare). After washing steps in TBS-T and
then in TBS, the bands were visualized using a
Typhoon TRIO+ scanner. Fluorescent intensities were
quanti f ied using the ImageQuant TL software.
Differences between APP/PS1 and B6 samples were sta-
tistically analyzed using Student’s t test. Differences be-
tween 3-, 6-, and 9-month-old age groups were statisti-
cally analyzed using one-way ANOVA Tukey post hoc
analysis.
Results
Distribution of Aβ Plaques
Our studies confirmed that 3-month-old APP/PS1 mice
do not develop amyloid deposits (Fig. 1e). The amyloid
plaques appear at 6 months of age in transgenic animals
(Fig. 1f), while hippocampus and cerebral cortex show
high amyloid burdens (Fig. 1g) at 9 months of age.
Mice from line B6 (controls) show no amyloid deposi-
tion throughout the aging (Fig. 1a–c). The timing of Aβ
plaque formation reproduced data known from previous
studies [30, 31]. We found amyloid plaques both at
light (Fig. 1d) and at electron microscopy levels
(Fig. 1h).
Fig. 1 Representative light microscopy images of 3-, 6-, and 9-month-
old B6 control (a–c) and APP/PS1 transgenic mice (e–g) hippocampal
and cortical brain regions. White arrows indicate amyloid plaque that
appears in 6- and spread in 9-month-old APP/PS1 mice brain. Higher-
magnification image of an amyloid plaque stained with reduced osmium
(d). Low-power electron micrograph of the same amyloid plaque as
shown in d (h). Scale bars: a–g 500 μm, d, h 20 μm (CA1 cornu
ammonis 1, DG dentate gyrus, cc corpus callosum)
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Proteomic Examination by Two-Dimensional Differential
Gel Electrophoresis
2D-DIGE Spot Changes and Protein Identification
by nanoUHPLC-MS/MS
We detected approximately 1200 quantitatively measur-
able spots per gel with 2D-DIGE (full stain labeling) in
sMito and nsMito fractions from brain tissues of 3-, 6-,
and 9-month-old APP/PS1 mice (altogether 6 × 12 gels).
Forty-three different nsMito proteins (3 months nsMito:
21; 6 months nsMito: 30; 9 months nsMito: 25) and 42
sMito proteins (3 months sMito: 24; 6 months sMito:
19; 9 months sMito: 19) were significantly changed in
APP/PS1 mice compared to B6 mice by more than 1.1-
fold change (there were common proteins between dif-
ferent age groups). Representative 2D-DIGE gel images
with differentially expressed sMito and nsMito spots are
shown in Fig. 2a, e, respectively. Fold changes of fluo-
rescence intensities between control and transgenic
sMito sample spots (Fig. 2b–d) were in the range of
−1.41 to 1.80 and in the range of −2.29 to 1.52 in
the nsMito samples (Fig. 2f–h).
Proteins of significantly changed spots (p < 0.05,
Student’s t test calculated in BVA module of the
DeCyderTM 2D software 7.0) were identified by LC/
MS-MS analysis. We described a total of 60 different
proteins (Table 1). Several proteins were present in
more than one spot suggesting posttranslational modifi-
cation or the presence of protein isoforms.
Functional Clustering of Mitochondrial Protein Changes
The identified, altered proteins participate in a variety of
mitochondrial processes including tricarboxylic acid
(TCA) cycle (n = 11), electron transport chain (ETC)
(n= 15), oxidative stress and apoptosis (n= 10), protein
transport mechanism (n = 2), mitochondrial protein
synthesis and folding (n= 4), glycolysis and gluconeogen-
esis (n= 2), nucleotide metabolism (n = 4), ketone body
metabolism (n= 2), lipid metabolism (n= 2), amino acid
metabolism (n= 2), lactate metabolism (n= 1), glutathione
metabolism (n= 1), synaptic transmission (n = 1), signal
transduction (n = 1), and others with unknown function
(n= 2) (Table 1, Fig. 3). We also depicted the significant
synaptic (Fig. 4a) and non-synaptic mitochondrial protein
changes (Fig. 4b) on the basis of mitochondrial biochem-
ical pathways in each age group.
Expressions of ETC proteins changed in the greatest
extent. Two subunits of complex I, NADH dehydrogenase
[ubiquinone] flavoprotein 2 (Ndufv2) (1.50-fold change)
and NADH dehydrogenase [ubiquinone] iron-sulfur pro-
tein 8 (Ndufs8) (1.77-fold change), showed the highest
protein-level changes in the 6 months of age sMito
(Table 1). Proteins belonging to the ETC showed both
increased and decreased levels in APP/PS1 model in cor-
relation with age.
The majority of proteins belonging to the TCA cycle
showed downregulation at 3-month-old age, both in
sMito (Fig. 4a) and nsMito (Fig. 4b). Interestingly, at
6 months of age, most of these proteins showed in-
creased levels, which might reflect a compensatory
mechanism. In the 9-month-old late phase, TCA cycle
proteins showed bidirectional changes. Among these
proteins, pyruvate dehydrogenase E1 component subunit
alpha somatic form (Pdha1) (1.56-fold change) and ma-
late dehydrogenase (Mdh2) (1.72-fold change) showed
the highest alterations. Expression levels of both these
proteins were increased in the 6 months of age sMito,
as well (Fig. 4).
Serine protease Htra2/Omi (Htra2) and persulfide
dioxygenase ETHE1 (Ethe1) showed the greatest synap-
tic mitochondrial protein changes involved in oxidative
stress response and apoptosis. These proteins showed
parallel expression level changes in the different age
groups (↓↑↓). These findings were also validated with
Western blot (WB) (Fig. 5).
Bioinformatics Analysis of Mitochondrial Protein
Changes
We found 17 different common regulator proteins. Based
on the UniProt and Gene Ontology databases, the com-
mon regulators are important cytokines (n = 3), protein
kinases (n = 3), transcription factors (n = 3), activators
(n = 3), hormones (n= 2), inhibitors (n= 2), and a chaper-
one (n= 1) (Fig. 6a). Regulator proteins showing remark-
ably high number of relationships were Sp1 (transcription
factor Sp1), insulin (INS), angiotensinogen (Agt), and
tumor necrosis factor (TNF) alpha (9, 10, 10, and 14
relationships, respectively, with the altered mitochondrial
proteins).
We found ten different common target proteins. Based
on the UniProt and Gene Ontology databases, the
Fig. 2 Representative 2D-DIGE image with labeled locations of
synaptic mitochondrial significant protein changes on the gel (a). Fold
changes of the synaptic mitochondrial proteins of 3 (b)-, 6 (c)-, and 9-
month-old animals (d). Representative 2D-DIGE image with labeled
locations of non-synaptic mitochondrial significant protein changes on
the gel (e). Fold changes of the non-synaptic mitochondrial proteins of
3- (f), 6- (g), and 9-month-old animals (h). All identified protein spots are
circled. Pink, turquoise, and yellow circles indicate significant protein
spot changes of 3-, 6-, and 9-month-old animals, respectively. The spot
numbers above the circles refer to the major genes identified in the
particular spot and described in Table 1
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Table 1 Protein differences between APP/PS1 and B6 mouse synaptic and non-synaptic mitochondria arranged in functional clusters
Acc. No Gene Protein name 3nsm 6nsm 9nsm 3sm 6sm 9sm Human AD brain
Tricarboxylic acid cycle (mitochondrial matrix)
1,17 -1,23 1,24
1,21 -1,13 1,29
P35486 Pdha1 Pyruvate dehydrogenase E1 component subunit alpha  somatic form -1,34 1,56 Decreased PDH activity (28)
Q9D051 Pdhb Pyruvate dehydrogenase E1 component subunit beta 1,18 1,27 Decreased PDH activity (28)
-1,12 1,15 1,31 -1,27
-1,31
Q9D2G2 Dlst
Dihydrolipoyllysine-residue 
succinyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial
-1,25 Decreased PDH activity (28)
-1,21 1,40 -1,19 1,23
1,39 -1,21 1,31
-1,22 1,36
-1,22 1,41
1,41
Q9D6R2 Idh3a Isocitrate dehydrogenase [NAD] subunit alpha -1,69 -1,19 -1,26 -1,31 1,44 Decreased ICDH activity (28; 23; 
86)
O08749 Dld Dihydrolipoyl dehydrogenase (KGDHC E1 component) 1,33 -1,22
Decreased KGDHC activity (28; 
86; 87)
1,18 -1,18
1,15
-1,26 -1,62 -1,25 -1,29
-1,10
1,22
-1,42 1,11 1,72 -1,25
-1,40 1,20
-1,20
Electron transport chain (inner mitochondrial membrane)
-1,29 1,16 1,50 -1,18
1,18 -1,38
Q91VD9 Ndufs1 NADH-ubiquinone oxidoreductase 75 kDa subunit 1,23 1,28
Decreased Ndufs1 level in 
parietal cortex (26)
Q8K3J1 Ndufs8 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8 -1,28 1,33 1,77 Decreased Complex I level (89)
Q7TMF3 Ndufa12 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 -1,13 -1,20 Decreased Complex I level (89)
-1,18 1,16 1,11
1,23
1,35
Q9CR68 Uqcrfs1 Cytochrome b-c1 complex subunit Rieske, mitochondrial -1,14 no human data
P99028 Uqcrh Cytochrome b-c1 complex subunit 6 1,21 no human data
P12787 Cox5a Cytochrome c oxidase subunit 5A 1,19 Decreased Cox5a activity (90; 91; 92)
1,15 1,38 -1,14 1,22
1,32 -1,26
-1,21 1,10 -1,17 1,10 1,10 -1,14
-1,17
Q9DCX2 Atp5h ATP synthase subunit d 1,14 -1,16 Increased Atp5h level if Complex I is inhibited (95)
Q9DB20 Atp5o ATP synthase subunit O -1,17 Decreased ATP synthase activity in Braak stages I/II (93)
-1,36 -1,16 -1,12 -1,13 -1,18
1,13
Q9DCW4 Etfb Electron transfer flavoprotein subunit beta -1,19 no human data
Q8K1Z0 Coq9 Ubiquinone biosynthesis protein COQ9 -1,24 no human data
Decreased PDH activity (28)
Decreased Aco2 activity (85); 
Decreased Aco2 level in 
Substantia nigra, Increased 
level in Cortex (30)
no human data
Decreased ATP synthase 
activity in Braak stages I/II (93); 
Atp5a1 associate with NFT 
degeneration (94)
Decreased Atp5b mRNA level 
in cortex (94)
no human data
Decreased PDH activity (28)
Increased Mdh2 activity (28; 86)
Decreased Fh activity in frontal 
cortex (84)
Decreased Ndufv2 level in 
temporal and occipital cortex 
(26)
Q8BMF4 Dlat
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase 
complex
Q99KI0 Aco2 Aconitate hydratase
Pyruvate dehydrogenase protein X componentPdhxQ8BKZ9
P56480 Atp5b ATP synthase subunit beta
P67778 Phb Prohibitin
Sucla2Q05BC6
P97807
Q03265 Atp5a1
P08249 Mdh2
Fh
Q9CZ13 Uqcrc1
Q9D6J6 Ndufv2
Succinyl CoA ligase ADP forming  subunit beta  
ATP synthase subunit alpha
Malate dehydrogenase
Fumarate hydratase
Cytochrome b-c1 complex subunit 1
NADH dehydrogenase [ubiquinone] 
flavoprotein 2
no human data
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Table 1 (continued)
Acc. No Gene Protein name 3nsm 6nsm 9nsm 3sm 6sm 9sm Human AD brain
Oxidative stress and apoptosis (mitocondrial matrix, intermembrane space, cytoplasm)
Q9DCM0 Ethe1 Persulfide dioxygenase ETHE1 -1,38 1,78 -1,13 no human data
P08228 Sod1 Superoxide dismutase [Cu-Zn] -1,25 1,36
Increased plasma Sod1 level in 
Alzheimer type dementia 
patients (93)
1,17 -1,19 -1,11 1,11
1,12
Q61171 Prdx2 Peroxiredoxin-2 1,19 Increased Prdx2 level (88)
1,10 1,31 1,24 -1,29 1,14
1,17
-1,20 1,38 1,19 -1,18 -1,27
-1,18 -1,10 1,24 -1,20
-1,18
-1,14
Q9JIY5 Htra2 Serine protease HTRA2 -1,41 1,80 -1,42 Increased Htra2 activity (29)
-1,56 1,21 1,34
-1,09 1,52 -1,26
Q60930 Vdac2 Voltage-dependent anion-selective channel protein 2 1,14
Increased Vdac2 level in 
temporal ctx (67)
Protein transport mechanism (outer/inner mitochondrial membrane)
1,48
1,39
Q9D880 Timm50 Mitochondrial import inner membrane translocase subunit TIM50 -1,34 -1,18
Aβ transport via TIM23                   
(100, 101)
Mitochondrial protein synthesis and folding (mitochondrial matrix)
1,20 1,40 1,25
1,27 1,19
1,18
P38647 Hspa9 Stress-70 protein 1,23 1,39 Decreased mRNA level (102)
Q8BFR5 Tufm Elongation factor Tu -1,18 1,25 HNE-modified Tufm in MCI brain (103)
Q3UGW4 Clpp ATP-dependent Clp protease proteolytic subunit -1,19 no human data
Glycolysis and gluconeogenesis (mitochondrial matrix)
-1,26
1,20
1,23
P17751 Tpi1 Triosephosphate isomerase -1,22 Aβ induce Tpi nitrotyrosination 
(104)
Nucleotide metabolism (mitochondrion)
Q9WUR9 Ak4 Adenylate kinase isoenzyme 4 (matrix) 1,16 -1,12 Increased Ak level (105)
P15532 Nme4 Nucleoside diphosphate kinase (intermembrane space) -1,27 Decreased Nme4 activity (27)
P30275 Ckmt1 Creatine kinase U-type (inner mitochondrial 
membrane) -1,15
Decreased Ckmt1 in Substantia 
nigra and Cortex (30)
Q8K4Z3 Apoa1bp NAD(P)H-hydrate epimerase                                      (Apolipoprotein A-I-binding protein) -1,16 no human data
Ketone bodies metabolism (mitochondrial matrix)
Q9D0K2 Oxct1 Succinyl-CoA:3-ketoacid-coenzyme A transferase 1 -1,30 1,29 Increased Oxct level (106)
Q8QZT1 Acat1 Acetyl CoA acetyltransferase 1,32 1,17 no human data
Lipid metabolism (mitochondrial matrix)
-1,30 -1,15 -1,19 -1,14
-1,15
-1,22 1,26
1,35
Amino acid metabolism (mitochondrial matrix)
Q8QZS1 Hibch 3-hydroxyisobutyryl-CoA hydrolase -1,18 no human data
Q9CWS0 Ddah1 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 -1,25
Oxidatively modified Ddah1 in 
inherited AD brain (108)
Decreased Hadha level (107)
O08709
P63038 Hspd1 60 kDa heat shock protein 
no human data
Enoyl-CoA hydratase
Q8BMS1 Hadha Trifunctional enzyme subunit alpha
Q8BH95 Echs1 no human data
Increased Hspd1 level if 
Complex I is inhibited (95)
Decreased Vdac1 level in 
cortex (99)
Decreased Prdx3 level (88; 97)
Increased Sod2 level in plasma 
(96)
Increased Prdx6 level in 
astorctes (98)
Prdx5
Sod2 Superoxide dismutase [Mn]P09671
Peroxiredoxin-5 
Glycerol 3 phosphate dehydrogenase (matrix)Gpd2Q64521
Voltage-dependent anion-selective channel 
protein 1Vdac1
Q9CZW5 Tomm70a Mitochondrial import receptor subunit TOM70
Q60932
Prdx6
P20108 Prdx3
P99029
Aβ transport via TOM complex 
(100, 101)
no human data
Thioredoxin-dependent peroxide reductase 
Peroxiredoxin-6
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common target proteins are protein kinases (n = 3),
caspases (n = 2), a cytokine (n = 1), an oxidoreductase
(n = 1), an electron transporter (n = 1), or anti-apoptotic
proteins (n= 2) (Fig. 6b). Target proteins showing remark-
ably high number of relationships were glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), apoptosis regulator
Bcl-2 (oxidoreductase BCL2), anti-apoptotic protein, and
cytochrome c (Cycs) electron transporter (9, 10, and 11
relationships, respectively, with the altered mitochondrial
proteins).
Table 1 (continued)
Acc. No Gene Protein name 3nsm 6nsm 9nsm 3sm 6sm 9sm Human AD brain
Lactate metabolism (mitochondrion, cytoplasm)
P16125 Ldhb L-lactate dehydrogenase B chain -1,42 Decreased Ldhb level in Cortex and Hippocampus (30)
Glutathione metabolism (mitochondrion, cytoplasm)
P19157 Gstp1 Glutathione S-transferase P 1 -1,49 Gstp1 gene polymorphism influence the risk of AD (109)
Synaptic transmission (mitochondrion, synapse)
O55042 Snca Alpha-synuclein -1,24
Increased Snca level in 
amygdala, limbic areas and 
inferior temporal gyrus (110; 111; 
112)
Signal transduction (mitochondrion, synapse)
O55042 Pebp1 Phosphatidylethanolamine-binding protein 1 -2,29 -1,15 Decreased Pebp mRNA level in hippocampus (65)
Others (mitochondrion, cytoplasm)
D3Z0L4 Chchd3 Coiled-coil-helix-coiled-coil-helix domain-containing protein 3 -1,17 no human data
Q9D172 D10Jhu81e ES1 protein homolog -2,04 1,47 -1,40 no human data
The color gradients of red (elevated protein level) to blue (reduced protein level) were used to show the differential abundances of APP/PS1 mitochon-
drial proteins (the numbers represent the average ratio values). Red text indicates the increased, and blue indicates the decreased protein levels in human
AD brain or plasma samples (sm synaptic mitochondria, nsm non-synaptic mitochondria; 3, 6, and 9: the age of animals in months). Green indicates the
proteins that are already known as binding partners of Aβ oligomer
Fig. 3 Functional clustering of mitochondrial protein changes
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Validation of Htra2 and Ethe1 Protein Changes with WB
For WB analysis, sMito samples were used from APP/PS1
and B6 animals. Htra2 and Ethe1 levels were analyzed in 3-
and 6-month-old sMito samples (n=6 samples per group).
The densitometry data of protein band intensities were ana-
lyzed with ImageJ software (NIH, Bethesda). The protein
levels of Htra2 in 3- (0.68±0.08) and 9-month-old APP/PS1
mice (0.70±0.06) were significantly decreased (p<0.001),
while the protein levels of Htra2 in 6-month-old APP/PS1
mice (1.28± 0.07) were significantly increased (p<0.001),
compared to B6 mice. Similar to the dynamic of Htra2 protein
changes, the protein levels of Ethe1 in 3- (0.74±0.08) and 9-
month-old APP/PS1 mice (0.68±0.05) were significantly de-
creased (p<0.001), while the protein levels of Htra2 in 6-
month-old APP/PS1 mice (1.51±0.16) were significantly in-
creased (p<0.001), compared to B6 mice. Thus, the WB re-
sults of these proteins confirmed the 2D-DIGE data (Fig. 5).
The normalized Htra2 and Ethe protein levels (APP/B6 den-
sitometric value) were significantly increased in 6-month-old
compared to 3-month-old mice. Furthermore, both proteins
were significantly decreased by 9 months compared to
6 months of age (p<0.001) (Fig. 7).
Discussion
We present here the first comprehensive study of protein net-
work changes in sMito and nsMito at different ages of pro-
gression of APP and Aβ accumulation in APP/PS1 mice.
Significant changes of 60 different mitochondrial proteins
Fig. 4 Mitochondrial localization of altered synaptic (a) and non-synaptic
(b) mitochondrial proteins in 3-, 6-, and 9-month-old APP/PS1 brain.
Green, yellow, and orange background indicates proteins from 3-, 6-,
and 9-month-old APP/PS1 animals, respectively. Protein transport:
TOM translocase of the outer membrane, Tim23 translocase of the inner
membrane subunit 23,MIAmitochondrial intermembrane space assembly,
SAM sorting and assembly machinery, Tim22 translocase of the inner
membrane subunit 22. Protein synthesis and folding: Hsp70 70 kDa heat
shock protein, Hsp60 60 kDa heat shock protein, EFTu elongation factor
Tu. Nucleotide metabolism: AK4 adenylate kinase 4, NDK nucleoside
diphosphate kinase, U-MtCK ubiquitous mitochondrial creatine kinase.
Electron transport chain: I complex I, II complex II, III complex III,
Cytc cytochrome complex, IV complex IV, V complex V. Tricarboxylic
acid cycle: CS citrate synthase, ACO aconitase, ICDH isocitrate
dehydrogenase, aKG alpha-ketoglutarate, aKGDH alpha-ketoglutarate
dehydrogenase, Succ-CoA succinyl-CoA, AcAc acetoacetate, AcAc-CoA
acetoacetyl-CoA, SCOT succinyl-CoA:3-ketoacid CoA transferase, Succ
succinate, FH fumarate hydratase, MDH malate dehydrogenase, OAA
oxaloacetic acid. Ketone body metabolism: ACAT acetyl-CoA
acetyltransferase. Fatty acid metabolism: ACADH acyl-CoA
dehydrogenase, ECAH enoyl-CoA hydratase, HADH hydroxyacyl-
coenzyme A dehydrogenase, KCAT 3-ketoacyl-CoA transferase.
Apoptosis: Htra2 serine protease HTRA2, Smac second mitochondria-
derived activator of caspases. Oxidative stress: MnSOD manganese
superoxide dismutase, PRX3 peroxiredoxin 3, PRX5 peroxiredoxin 5,
ETHE1 persulfide dioxygenase ETHE1. Ion transport: ANT adenine
nucleotide translocase
Fig. 5 Western blot validation of changes in Ethe1 and Htra2 expression
in synaptic mitochondria of 3-, 6-, and 9-month-old APP/PS1 mice.
Densitometric analysis was performed for Ethe1 and Htra2 (n= 6). The
levels of Ethe1 and Htra2 were significantly decreased in synaptic
mitochondria of 3 and 9, while significantly increased in 6-month-old
APP/PS1 mice. Representative immunopositive bands are shown under
the diagram. (Student’s t tests, ***p < 0.001; **p < 0.01; error bars
indicate SEM)
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were identified by comparing of APP/PS1 to B6 mice
(Table 1). The majority of significant protein changes
were related to energy metabolism (ETC and TCA cycle),
oxidative stress response, and apoptosis.
Based on common regulator and target analysis of al-
tered proteins of sMito and nsMito, we conclude that reg-
ulator and target proteins being in direct interaction with
proteins changed in APP/PS1 mice are involved in in-
flammation and apoptotic pathways (Fig. 6). TNF as a
common regulator and target has the highest number of
relationships suggesting a pivotal role of TNF in Aβ-
mediated mitochondrial protein changes in parallel with
Aβ accumulation in the mitochondria. TNF is a proin-
flammatory cytokine, which is a key initiator of inflam-
mation in the brain and is also involved in neurotoxicity,
neuronal death, and dysfunction [35]. Increasing amount
of data suggests the involvement of TNF in human AD.
Aβ was found to stimulate secretion of TNF [36, 37] and
other inflammatory mediators in the brain [38, 39].
Furthermore, Aβ-induced neuroinflammation is an early
step in neurodegeneration [40]. In accordance with the
results of animal model studies, a 25-fold elevation of
TNF level was observed in the cerebrospinal fluid of
AD patients [41]. TNF level is in good correlation with
clinical progression of AD [42]. Inhibition of TNF signal-
ing prevents pre-plaque Aβ-associated neuropathology
[43], while an anti-TNF therapy efficiently improved the
cognition of AD patients [44–46]. Our results suggest that
TNF contributes to early appearance of mitochondrial
proteome changes. We raise the possibility that TNF
could be an early indicator of initial phase of Aβ
accumulation; however, it should be tested in human AD
subjects in a non-invasive manner. The results of bioin-
formatics studies in APP/PS1 mice model proteomics
revealed that TNF-α-induced extrinsic and Htra2-,
Ethe1-, phosphatidylethanolamine-binding protein 1
(Pebp1)-, and Vdac1-related mitochondrial apoptotic
pathways suggest the importance of Aβ effect on nuclear
factor kappa B (NF-κB) signaling and caspase cascade
pathways (Fig. 7).
Htra2 is a member of the high-temperature require-
ment (HtrA) family of oligomeric serine proteases,
participating in several cellular processes including mi-
tochondrial function, autophagy, and apoptosis. Several
studies have demonstrated the essential role of Htra2 in
pathogenesis of Parkinson’s disease [52, 53], but its role
in AD is not clear. Enzymatic activity of Htra2 in-
creases in frontal cortex of AD patients [28]; moreover,
Htra2 accumulates in the cerebral cortex and hippocam-
pus and is also present in senile plaques and
Fig. 6 Common regulator (a) and target (b) analysis of altered
mitochondrial proteins. Blue edges indicate the relationships between
common regulators/targets and altered mitochondrial proteins. Yellow
indicates mitochondrial proteins that were significantly changed and have
common targets or regulators (full protein names are present in Table 1).
Green indicates the common regulator (a) or target (b) proteins. NFE2L2
nuclear factor erythroid 2-related factor 2, IL1B interleukin-1 beta,MAPK1
mitogen-activated protein kinase 1, TNF tumor necrosis factor,AKT1RAC-
alpha serine/threonine-protein kinase, APP amyloid beta A4 protein, AGT
angiotensinogen, TGFB1 transforming growth factor beta-1, MYC myc
proto-oncogene protein, INS insulin, PPARGC1A peroxisome proliferator-
activated receptor gamma coactivator 1-alpha, SP1 transcription factor Sp1,
TP53 cellular tumor antigen p53, HSPA1A heat shock 70 kDa protein 1A/
1B, PPARA peroxisome proliferator-activated receptor alpha, TXN
thioredoxin, MAPK8 mitogen-activated protein kinase 8, CASP9 caspase-
9, CYCS cytochrome c, MAPK14 mitogen-activated protein kinase 14,
GAPDH glyceraldehyde-3-phosphate dehydrogenase, CASP3 caspase-3,
BCL2 apoptosis regulator Bcl-2
Fig. 7 The TNF-α (common regulator and target protein)-induced
extrinsic and the Aβ-mediated Htra2-, Ethe1-, Pebp1-, and Vdac1-
related mitochondrial apoptotic pathway connections. The
regulation pathways suggest the importance of Aβ effect on NF-
κB signaling and caspase cascade pathways. AIP ASK1-interacting
protein 1, ASK1 apoptosis-signal-regulating kinase-1, BID Bcl-2 B
cell lymphoma 2 agonist, tBID truncated BID, BAX B cell
lymphoma 2-associated protein X, pJNK phospho c-Jun amino
(N) terminal kinase, AP1 activator protein-1, c-jun c-Jun amino
(N) terminal kinase, CypD cyclophilin-D, Ethe1 persulfide
dioxygenase Ethe1, FAD FAS-associated death domain, FLICE
FADD-like interleukin-1β, Htra2 serine protease Htra2, NIK NF-
kappaB-inducing kinase, IKK IkappaB kinase, IκB inhibitory
subuni t of NF-κB, IAP inhib i tor of apoptos is , Pebp1
phosphatidylethanolamine-binding protein 1, PS1 presenilin-1,
RIP receptor-interacting protein, TNFR1 TNF receptor 1, TRADD
TNF-receptor death domain, TRAF: TNF-associated factor 2,
Vdac1: Voltage-dependent anion-selective channel protein-1.
According to [47–51] and own data
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neurofibrillary tangles [54]. Furthermore, APP is directly
cleaved by the Htra2 [55, 56]. Htra2 also interacts with
Aβ, contributing to its proapoptotic activity [57]. The
Htra2-mediated processing of APP is a physiological
process in normal brain [55]. Mitochondrial Htra2 could
interact with PS1 [47, 58–61]. PS1-derived peptides
binding to the PDZ domain of Htra2 can induce apo-
ptosis [47] (Fig. 7). In conclusion, increased Htra2 level
enhances Htra2-mediated APP processing that counter-
balances the amyloidogenic cleavage of APP. This
mechanism might slow down accumulation of Aβ in
the 6-month-old APP/PS1 mice. In this way, Htra2
increase could represent a temporary protective mecha-
nism against further Aβ overexpression at the 6-month-
old mice.
Ethe1 plays an essential role in hydrogen sulfide ca-
tabolism. Ethe1 is an anti-apoptotic protein, which in-
creases the deacetylase activity of p53 in association
with histone deacetylase 1 leading to the suppression
of apoptosis [62]. Ethe1 also inhibits NF-κB signaling
by binding to RelA and accelerating its export from the
nucleus [48] (Fig. 7). Loss of Ethe1 causes fatal sulfide
toxicity in ethylmalonic encephalopathy which is an au-
tosomal recessive, invariably fatal disorder [63]. The
role of Aβ accumulation-induced pathomechanism has
not yet been described. According to our data-driven
working hypothesis, the increased Ethe1 level in 6-
month-old sMito might prevent Aβ-induced apoptotic
processes that could be a compensatory mechanism
against moderate amyloid accumulation.
Pebp1 (also known as Raf kinase inhibitor protein
(RKIP)) is a multifunctional protein. It is the precursor
of hippocampal cholinergic neuro-stimulating peptide
(HCNP). In our study, Pebp1 showed decreased protein
expression in the 9-month-old mouse only, where amy-
loid plaques are present in the brain. Many studies
showed that Pebp1 plays a pivotal modulatory role in
different signaling cascades. It inhibits the MAPK sig-
naling pathway Ras/Raf-1/MEK/ERK by inhibition of
Raf-1 phosphorylation and activation [64] and, more-
over, inhibits TNF-α-induced activation of the NF-κB
pathway [49] (Fig. 7). The expression of Pebp1
mRNA was decreased in the hippocampal CA1 field in
patients of late-onset AD. Since HCNP stimulates the
enzymatic activity of choline acetyltransferase in neu-
rons, its low concentration in AD patients because of
its decreased precursor Pebp1 could explain the down-
regulation of cholinergic neurons associated with the
memory loss in AD [65]. We note here that Pebp1 de-
creases in another AD model mouse Tg2576 in accor-
dance with development of amyloid plaques [66]. Our
data confirm importance of Pebp1 in AD pathogenesis
in APP/PS1 mice model.
Voltage-dependent anion-selective channel proteins
(VDACs) are pore-forming proteins found in the mito-
chondrial membrane of all eukaryotes and postsynaptic
membranes in the brain. Our results demonstrated that
Vdac1 decreased in 6-month-old APP/PS1 mice
synaptic mitochondria samples, while increased in
9-month-old ones. The non-synaptic mitochondrial
Vdac1 showed changes in both directions in different
protein spots. VDACs regulate anion fluxes of metabo-
lites including ATP and regulate mitochondrial metabo-
lism. In human postmortem brains of AD subjects,
Vdac1 was significantly reduced in temporal and frontal
cortex and thalamus [67]. Other experiments demon-
strated that Vdac1 is elevated in AD affected regions
of postmortem brains and cortical tissues of APP trans-
genic mice. Vdac1 is linked to Aβ and phosphorylated
tau in human postmortem brains of AD patients and
different AD mouse models. Vdac1 increase blocks the
mitochondrial permeability transition (MPT) pores, dis-
rupts the transport of mitochondrial proteins and metab-
olites, impairs gating of VDAC, and causes defects in
oxidative phosphorylation, leading to mitochondrial dys-
function in AD neurons [68–70] (Fig. 7). Vdac1 is also
overexpressed in the hippocampus of amyloidogenic AD
transgenic mice models. Furthermore, soluble Aβ oligo-
mers were able to induce upregulation of Vdac1 in a hu-
man neuroblastoma cell line [70]. Reduced Vdac1 expres-
sion may be beneficial to synaptic activity, may improve
function, and may protect against toxicities of AD-related
genes including AβPP, Tau, PS1, PS2, and BACE1 [71].
In detergent-resistant membranes, Vdac1 also associates
with γ-secretase and affects Aβ production, suggesting
that VDAC is a putative target for drug development
against AD [72]. In conclusion, the decreased synaptic
mitochondrial Vdac1 level in 6 months of age APP/PS1
mice may improve synaptic function, while increased lev-
el in older age might correlate with synaptic loss and
memory impairment.
It is important to note that beside Aβ, an increasing
level of AICD peptide could also mediate several pro-
cesses in APP/PS1 mice. Although AICD can be gener-
ated by both α-γ and β-γ-secretase cleavages, its exact
role remains controversial [73]. The AICD-mediated nu-
clear signaling occurs predominantly through the
amyloidogenic processing pathway [74]. Moreover,
AICD can interact with different intracellular adaptor
proteins as signaling molecules [75]. AICD can translo-
cate to the nucleus, forms multiprotein complexes, and
regulates its own precursor’s expression (APP) [76].
Furthermore, AICD acts as a positive regulator of apo-
ptosis [77–79] and modulates inflammation-associated
calcium homeostasis and ATP metabolism linked to mi-
tochondrial bioenergetics function [80]. APP and AICD
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also increase the expression of mitochondrial proteins,
such as mitochondrial master transcriptional coactivator
PGC-1a and its target genes [81], so APP processing
may also regulate synaptic and non-synaptic mitochon-
drial protein changes in APP/PS1 mice.
One of the main interests of AD research nowadays
is to find early markers to select and cluster high-risk
people, which could be the first step for causal treat-
ment of AD. Our results revealed some early changes of
mitochondrial proteome that are present before any neu-
rological symptoms of AD appear. To estimate the
translational value of our findings, it is noteworthy that
46 out of the 60 altered proteins have already been
known to change in the late stage of human AD
(Table 1/Human AD brain column, established from
postmortem or autopsy confirmed AD samples). We
identified 11 proteins already known as direct binding
partners of human Aβ oligomers (Table 1/green
labeling) [72], suggesting that binding of Aβ to
mitochondrial proteins is a major mechanism of its met-
abolic action.
In summary, our results demonstrate a different and age-
dependent effect on synaptic and non-synaptic mitochon-
drial proteome in APP/PS1 mouse model of APP overpro-
duction and Aβ accumulation. The majority of the signif-
icant protein changes were related to energy metabolism,
oxidative stress response, and apoptosis. Although the
levels of several mitochondrial proteins were altered at
early stage, no simultaneous alteration in hydrogen perox-
ide generation could be detected. This indicates functional
compensation of protein changes in early stage. Htra2 and
Ethe1 apoptotic proteins show an age-dependent change in
expression in sMito of APP/PS1 mice; thus, they could be
used as progression markers of Aβ accumulation. The re-
sult of bioinformatical analysis suggests a regulatory role
of TNF in Aβ-mediated mitochondrial protein changes.
Our findings also suggest that the translational value of
the results with mice is not negligible. Based on these find-
ings in mice, we suggest conducting research for early tests
of Htra2, Ethe1, Vdac1, Pebp1, and TNF level in further
independent models (like other transgenic mammal models
or mutant cell lines), together with in human CSF or plas-
ma which could lead to the establishment of early bio-
markers of high-risk population. We hope to open a new
path of research aiming early mitochondrial molecular
mechanisms of Aβ accumulation as a prodromal stage of
human AD.
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